What is the new ticker for 23andMe?
sunnyvale, calif., march 15, 2022 (globe newswire) -- 23andme holding co. (nasdaq: me) (“23andme”), a leading consumer genetics and therapeutics company with a mission to help people access,...
Is 23andMe still in business 2021?
Apr 03, 2022 · 23andMe Holding Co. (NASDAQ:ME) issued its quarterly earnings results on Thursday, February, 10th. The company reported ($0.21) earnings per share (EPS) for the quarter. The business earned $56.89 million during the quarter, compared to …
What does 23andMe do?
ME | Complete 23andMe Holding Co. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
How does 23andMe's insider ownership look like?
Apr 12, 2022 · SUNNYVALE, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results... 1 month ago - GlobeNewsWire 10 Top Penny Stocks To Buy Under $5 That Are Household Names
Is 23andMe on the stock market yet?
Via the use of a special purpose acquisition company (SPAC) that's owned and operated by Richard Branson, the billionaire founder of Virgin Group, 23andMe will become a publicly traded company in 2021.
Can you invest in 23andMe?
Unlike traditional IPOs, 23andMe is going public through a special purpose acquisition company (SPAC).Feb 1, 2022
How do I buy 23andMe shares?
How to buy shares in 23andMe HoldingCompare share trading platforms. Use our comparison table to help you find a platform that fits you.Open your brokerage account. Complete an application with your details.Confirm your payment details. ... Research the stock. ... Purchase now or later. ... Check in on your investment.
What will 23andMe stock price be?
$3.3900$ 3.4000CloseChgChg %$3.3900-0.0600-1.74%
Why is 23andMe stock so low?
23andMe's stock has tumbled as a result of its weak revenue growth. New income from drug development collaborations could increase over time. It's difficult to value an enterprise that's in the midst of a pivot.Feb 16, 2022
Is 23andMe a profitable company?
At the same time, 23andMe has struggled with plummeting revenues and significant losses. It cut 100 employees (or 14% of its staff) in January 2020, before the pandemic, and saw its revenue drop 30% in the year ending March 2020, to $305 million, down from $441 million the previous year, according to company documents.Dec 1, 2021
Is me stock a buy or sell?
According to the issued ratings of 2 analysts in the last year, the consensus rating for 23andMe stock is Buy based on the current 1 hold rating and 1 buy rating for ME. The average twelve-month price target for 23andMe is 8.50 with a high price target of 11.00 and a low price target of 6.00.
How can I buy stocks in me?
Here are five steps to help you buy your first stock:Select an online stockbroker. The easiest way to buy stocks is through an online stockbroker. ... Research the stocks you want to buy. ... Decide how many shares to buy. ... Choose your stock order type. ... Optimize your stock portfolio.
What IPO means?
initial public offeringWhen a private company first sells shares of stock to the public, this process is known as an initial public offering (IPO). In essence, an IPO means that a company's ownership is transitioning from private ownership to public ownership. For that reason, the IPO process is sometimes referred to as "going public."
Is ME stock good to buy?
23andMe Holding Co. finds support from accumulated volume at $3.37 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. This stock has average movements during the day and with good trading volume, the risk is considered to be medium.
Who runs 23andMe?
Anne WojcickiAnne Wojcicki, the cofounder and CEO of 23andMe, owns 99.4 million shares of the merged company; with shares trading on the Nasdaq under the ticker “ME” at $13.40 as of 3:00pm EDT Thursday, her stake is worth approximately $1.3 billion.Jun 17, 2021
Who funds 23andMe?
DNA testing technology company 23andMe has raised just shy of $82.5 million in new funding, from an offering of $85 million in total equity shares, according to a new SEC filing. The funding, confirmed by the Wall Street Journal, comes from investors including Sequoia Capital and NewView Capital.Dec 29, 2020
Is 23andMe a buy right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last year. There are currently 1 hold rating and 1...
When is 23andMe's next earnings date?
23andMe is scheduled to release its next quarterly earnings announcement on Thursday, May 12th 2022. View our earnings forecast for 23andMe .
How were 23andMe's earnings last quarter?
23andMe Holding Co. (NASDAQ:ME) announced its quarterly earnings data on Thursday, February, 10th. The company reported ($0.21) earnings per share...
What guidance has 23andMe issued on next quarter's earnings?
23andMe issued an update on its FY 2022 earnings guidance on Thursday, February, 24th. The company provided earnings per share guidance of for the...
What price target have analysts set for ME?
2 analysts have issued 12 month price objectives for 23andMe's shares. Their forecasts range from 6.00 to 11.00. On average, they expect 23andMe's...
Who are 23andMe's key executives?
23andMe's management team includes the following people: Ms. Anne Wojcicki , Co-Founder, CEO, Pres & Director Mr. Steven J. Schoch , CFO & Treas...
Who are some of 23andMe's key competitors?
Some companies that are related to 23andMe include Arena Pharmaceuticals (ARNA) , Legend Biotech (LEGN) , Intra-Cellular Therapies (ITCI) , Per...
What is 23andMe's stock symbol?
23andMe trades on the NASDAQ under the ticker symbol "ME."
Who are 23andMe's major shareholders?
23andMe's stock is owned by a number of institutional and retail investors. Top institutional investors include Revelation Capital Management LLC (...
Headlines
23andMe (NASDAQ:ME) Frequently Asked Questions
Could The 23andMe Holding Co. (NASDAQ:ME) Ownership Structure Tell Us Something Useful?
Recently Viewed Tickers
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock.
23andMe Holding Co
Visit a quote page and your recently viewed tickers will be displayed here.
What is Weisslaw LLP investigating?
23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. It provides direct access to genetic information with multiple Food and Drug Administration authorizations for genetic health risk reports.
Who is the CEO of 23andme?
NEW YORK, Feb. 4, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of VG Acquisition Corp. ("VGAC" or the "Com...
Is 23andme a public company?
Jun.17 -- 23andMe Inc. CEO Anne Wojcicki discusses the DNA-testing company's NASDAQ trading debut, a collaboration on drug development with GlaxoSmithKline Plc, and the choice to go public through a mer...
Who is VG Acquisition Corp?
23andMe jumps on stock market debut, as privacy concerns about genetic testing abound. The company is the latest to go public via a SPAC deal. 23andMe, the direct-to-consumer genetic testing company headquartered in Sunnyvale, California, popped on its stock market debut Thursday. Other stocks mentioned: VGAC.
What is 23andme holding?
NEW YORK, June 10, 2021 /PRNewswire/ -- VG Acquisition Corp. (NYSE: VGAC), a special purpose acquisition company sponsored by Virgin Group ("VGAC" or the "Company") today announced that its shareholders...
What time do you trade in the pre market?
SUNNYVALE, SUNNYVALE, California, United States +1 800 239-5230 https://vgacquisition.com/. 23andMe Holding Co is a consumer genetics and research company. It helps people access, understand, and benefit from the human genome.
Does market cap include convertible securities?
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
What is 23andme data?
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
How much did 23andme raise in 2015?
Aggregated customer data is studied by scientific researchers employed by 23andMe for research on inherited disorders; rights to use customers' data is also sold to pharmaceutical and biotechnology companies for use in their research. The company also collaborates with academic and government scientists. In July 2012, 23andMe acquired the startup CureTogether, a crowdsourced treatment ratings website with data on over 600 medical conditions. 23andMe has an optional consent that enables the individual's genetic information to be included in medical research that may be published in a scientific journal. However, if an individual chooses not to consent for their 'personal information' to be used, their 'genetic information' and 'self-reported information' may still be used and shared with the company's third party service providers.
Why are 23andme results different?
In 2015, 23andMe raised $115 million in a Series E offering, increasing its total capital to $241 million. In June 2017, 23andMe created a brand marketing advertisement featuring Gru from the movie Despicable Me. In 2018, the company further marketed its brand with advertisements narrated by Warren Buffett.
When did Cusenza leave 23andme?
Some customers comparing 23andMe ancestry results to other genomic and ancestry testing companies have received differing results, possibly due to human error, or the differing analysis of the extracted DNA due to overrepresentation of one country or region over another in the database. Ancestry results are based on the amount of confidence the company has that the DNA is from a specific region, leading to both specific countries when the confidence is high, and broad regions when the confidence is low. This can lead to surprising results due to specific countries getting masked by low confidence in the DNA. In August 2018, the company said it was broadening its coverage of Africa and East Asia. The possibility of false positives also adds to customer confusion and unnecessary concerns when interpreting results.
When did 23andme stop testing?
Cusenza left the company in 2007 and was appointed CEO of Nodal Exchange in 2008. Avey left the company in 2009 and co-founded Curious, Inc. in 2011. In 2012, 23andMe raised $50 million in a Series D venture round, almost doubling its existing capital of $52.6 million.
Is 23andme FDA approved?
On December 5, 2013, 23andMe announced that it had suspended health-related genetic tests for customers who purchased the test from November 22, 2013 in order to comply with the FDA warning letter, while undergoing regulatory review.
How much is 23andme+?
According to Anne Wojcicki, 23andMe had been in dialogue with the FDA since 2008. In 2010, the FDA notified several genetic testing companies, including 23andMe, that their genetic tests are considered medical devices and federal approval is required to market them; a similar letter was sent to Illumina, which makes the instruments and chips used by 23andMe in providing its service. 23andMe first submitted applications for FDA clearance in July and September 2012.
How much revenue did 23andme make in 2019?
Since October 1, 2020, the company offers a new service called "23andMe+", priced at $29/year, for the customers of the "Health + Ancestry" service, who completed genotyping on version 5 of the microarray chip used by the company.
What is 23andme test?
In 2019, the company brought in $441 million in revenue, with consumer services accounting for 96% of sales. However, its forecast for this year amounts to just $243.5 million in sales. 23andMe is, fortunately, improving its operating income less noncash items from a loss of $85 million in 2019 to a positive $7.5 million this year.
What company did Virgin Group acquire?
23andMe is known for its namesake health and ancestry testing services. After purchasing and receiving its test kit, consumers ship a saliva sample to a laboratory for analysis. The results include a complete breakdown of the user's genetic background. Customers can also use the data to locate close relatives on the 23andMe platform.
Does 23andme have genetic testing?
On June 16, special purpose acquisition company (SPAC) Virgin Group Acquisition completed its merger with consumer genetics company 23andMe ( NASDAQ:ME). The deal funded the latter with $592 million in cash at a total enterprise valuation of $3.5 billion.
Who is Zhiyuan Sun?
Lastly, 23andMe is combining its genetic research and testing to curate a subscription service for its consumers. Each subscription offers insight into an individual's pharmacogenetics, heart health, DNA relatives, and polygenic risk scores (i.e., risk of developing cancer by a certain age).
ME Overview
Zhiyuan Sun is a statistician with a knack for analyzing clinical trials and company financials. Investing in healthcare and cannabis is his passion, as well as looking out for new, actionable stock investment ideas in these sectors. Fool since April 2020.
Zen Score
VG Acquisition Corp. intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business... read more
Due Diligence Checks
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ME scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Profit margin
ME's profit margin has decreased... subscribe to Premium to read more.
Assets to liabilities
ME's cash and short-term investments... subscribe to Premium to read more.
Cash flow
ME's short-term assets ($669.86M) exceed... subscribe to Premium to read more.
